Novartis/Fougera Pharma

Target: Fougera Pharma
Buyer: Novartis ($NVS)
Price: $1.5 billion
Closed: July 23, 2012

Novartis wanted more skin in the generics game, and it got it in specialty dermatology drugmaker Fougera Pharma. By adding Fougera's drugs to the portfolio held by Sandoz, the Swiss company's generics unit, it suddenly was the leader in dermatology knockoffs. The deal also promised to add some revenue as Novartis' top drug, Diovan, headed for generic competition irrelevance.

Novartis has plans to expand the business to take advantage of the growing number of branded dermatology drugs going off patent. It also sees opportunities to build it internationally. As Sandoz CEO Jeff George said at the time, "We see great potential to take a business that's a U.S. business and take it globally."

Novartis/Fougera Pharma

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.